WO2019153334A1 - Complex prebiotics regulating human intestinal function and use thereof - Google Patents

Abstract

Disclosed are complex prebiotics and a use thereof. The complex prebiotics comprise inulin, galacto-oligosaccharide, xylitol and yeast β-glucan, and have the use of regulating the human intestinal function.

Description

Compound prebiotic element for regulating human intestinal function and application thereof Technical field

The invention relates to a nutritional product, in particular to a composite prebiotic capable of regulating intestinal function of a human body and an application thereof.

Background technique

The intestine is the largest immune organ in the human body and the largest detoxification organ in the human body. It controls more than 70% of the body's immune function and becomes a natural barrier to maintain human health. As the saying goes: "The disease comes from the mouth", most of the bacteria are eaten from the mouth, and the main way for bacteria to enter the body is the intestines. It is not difficult to imagine that the health of the intestine depends on the activity of the intestines.

In 2012, the Chinese Nutrition Society conducted a one-month online survey of the “Civil Intestinal Health Survey”, involving a total of 14,581 people and 14566 valid samples. Statistics show that nearly 95% of people have intestinal problems, and the form is severe. Intestinal health problems are common. Intestinal health is related to many functions such as nutrient absorption, digestion of food, emotional control and immunity. Once the intestinal tract has problems, human health will be affected. The pace and way of life of modern people determines that intestinal health problems will persist for a long time.

Intestinal system diseases are related to lifestyle factors, genetic polymorphisms, food allergies, psychological factors, brain-intestinal axis abnormalities, and intestinal flora imbalance.

Digestive diseases interact with intestinal flora imbalance, causing each other. Under normal physiological conditions, colonic flora can ferment non-digestible food residues and metabolize endogenous mucus produced by epithelial cells to produce absorbable nutrients for the host. And energy to promote the growth and proliferation of bacteria. The dominant intestinal flora can also colonize the pathogens through competitive nutrient inhibition, and produce bacteriocins, short-chain fatty acids and other substances to degrade pathogen toxins and reduce their toxicity. The cecal and right colon (especially ileocecal) fermentation is very active, can produce a large number of short-chain fatty acids, such as acetic acid, propionic acid and butyric acid, etc., which is almost completely consumed by colonic epithelial cells, it is the colon The main source of energy; short-chain fatty acids can also delay the development of chronic ulcerative colitis, inhibit the formation of carcinogens or carcinogens, transform certain carcinogens into non-carcinogens, activate macrophages, and reduce the incidence of colon cancer Etc., through which mechanism the microorganisms exert their beneficial or unfavorable effects, further research is needed.

At present, there are two methods for adjusting the intestinal micro-ecological environment. One is the probiotic bacteria. Normal intestinal flora, especially bifidobacteria and lactic acid bacteria, play an important role in maintaining a good intestinal flora structure and the health of the body, but the viable bacteria in colonization, live bacteria survival rate, transport, preservation There are many shortcomings in the other aspects; the second is the self-enrichment of the probiotics in the intestine, that is, the prebiotics supplement bacteria. The physiological function of prebiotics is mainly achieved by promoting the reproduction of beneficial bacteria in the intestine and regulating the balance of intestinal micro-ecology, which is manifested in the improvement of intestinal function and the enhancement of immunity.

Although there are already prebiotic products on the market, many products are based on their individual physiological functions and effects according to each single component, such as inulin, galactooligosaccharide, xylitol, oligomannose, and dextran. The products formed by the cooperation are not considered to have the compatibility and influence of the components when used together.

Summary of the invention

In view of this, the present invention provides a composite prebiotic. The compound prebiotic is formulated according to science, thereby regulating the self-enrichment of probiotics in the intestine.

The present invention provides a composite prebiotic comprising inulin, galactooligosaccharide, xylitol and yeast beta-glucan, the prebiotic capable of regulating intestinal function in humans.

As a natural soluble dietary fiber, inulin is hardly hydrolyzed and digested by gastric acid, and is fermented by a large number of beneficial microorganisms in the colon. Therefore, it has various health care functions, such as regulating blood sugar, not causing blood sugar fluctuations, and not affecting blood glucose levels. And insulin content, improve intestinal function, promote mineral absorption and so on. Inulin can be used not only as a fat substitute for low-energy food production, but also as a dietary fiber and a physiological function of probiotics. It is an excellent functional food base.

Galactooligosaccharides (GOS) is a functional oligosaccharide with natural properties. Its molecular structure is generally linked to 1 to 7 galactosyl groups, ie Gal-(Gal)n, on galactose or glucose molecules. -Glc/Gal (n is 0-6). In nature, there is a trace amount of GOS in the milk of animals, and the content of human breast milk is high. The establishment of Bifidobacterium flora in infants depends largely on the GOS component in breast milk, which is an important prebiotic in breast milk. . GOS has the functions of promoting the growth of beneficial bacteria in the human intestinal tract, inhibiting the growth of intestinal spoilage bacteria, improving lipid metabolism, lowering serum total cholesterol concentration, and promoting the absorption of mineral elements, and has the characteristics of low calorie and good solubility. GOS is a low molecular weight water-soluble dietary fiber with low viscosity, strong moisturizing properties, no mineral binding, refreshing taste, low caloric value, sweetness of only 20% to 40% of sucrose, acid and heat. It has strong stability, and it will not decompose under the condition of 180 °C or pH 3. It has high coloring property, strong moisture retention ability, no bad texture and flavor, and is not digested by human digestive enzymes. It has good proliferative activity of bifidobacteria.

Xylitol is an intermediate in the metabolism of sugar in the body. In the absence of insulin in the body, it affects the metabolism of sugar. It does not require insulin. Xylitol can also be absorbed through the cell membrane, promoted by tissue absorption, and promotes the synthesis of glycogen in cells. And energy, and will not cause an increase in blood sugar levels.

Yeast β-glucan has physiological activities such as lowering cholesterol and blood lipids, and increasing immunity. Numerous studies have shown that the immunoregulatory mechanism of yeast β-glucan is that it can specifically bind to immune cells of animals and humans (including single cells, macrophages, neutrophils and natural killer cells) by stimulating animals. In vivo lymphocytes, which activate macrophages in animals to produce immune activity against the body. Therefore, yeast β-glucan has a multifaceted immune function.

In a specific embodiment of the invention, the composite prebiotic consists of inulin, galactooligosaccharide, xylitol and yeast beta-glucan.

In another embodiment of the invention, the composite prebiotic further comprises xylooligosaccharide.

Xylooligosaccharides are oligosaccharides composed of 2 to 7 xylose linked by β-1,4 glycosidic bonds, and some also contain arabinouronic acid and glucuronic acid side chains. The ingredients are Xylobiose (X2) and Xylotriose (X3). Xylo-oligosaccharide has the functions of promoting the growth of beneficial bacteria in the intestine, inhibiting the growth of harmful bacteria, and improving the intestinal micro-ecological environment. Xylo-oligosaccharide is one of the oligosaccharides found to have the best proliferative effect on bifidobacteria, so it is called super-strong bifid factor, and it has low effective dose (0.7g/d) and acid-heat stability. Good, good processing performance and a wide range of raw materials.

Xylo-oligosaccharides selectively promote the proliferation of bifidobacteria. There is no enzyme system for hydrolyzing xylooligosaccharides in the human gastrointestinal tract. Therefore, it is not digested and digested and directly enters the large intestine, and is preferentially utilized by bifidobacteria, and has an excellent activity for promoting the proliferation of bifidobacteria. Experiments have shown that the selectivity of xylo-oligosaccharide-proliferating Bifidobacterium is much higher than that of other functional oligosaccharides.

In another embodiment of the invention, the composite prebiotic further comprises oligomannose.

Oligomeric mannose is an oligosaccharide formed by linking D-mannose to a main chain through β-1,4 glycosidic bonds and linking glucose to a main chain or a branch. The degree of polymerization is between 2 and 10, which is a kind of oligosaccharide. The new type of prebiotics can activate and proliferate Bifidobacteria and lactic acid bacteria to regulate micro-ecological balance.

In another embodiment of the invention, the composite prebiotic consists of inulin, galactooligosaccharide, xylitol, xylooligosaccharide and yeast beta-glucan.

In another embodiment of the invention, the composite prebiotic consists of inulin, galactooligosaccharide, xylitol, oligomannose and yeast beta-glucan.

In still another embodiment of the present invention, the inulin is 40-200 parts by weight; the galacto-oligosaccharide is 10-140 parts; and the xylitol is 1-80 parts; The yeast β-glucan is 0.03-5 parts.

In still another embodiment of the present invention, the composite prebiotic comprises 40-200 parts of inulin, 10-140 parts of galacto-oligosaccharide, 1-80 parts of xylitol, and 0.03-5 parts by weight. Yeast β-glucan and 5-60 parts of xylooligosaccharide.

In still another embodiment of the present invention, the composite prebiotic comprises 70-150 parts of inulin, 20-100 parts of oligogalactose, 1-50 parts of xylitol, 0.05-3 parts by weight. Yeast β-glucan and 5-40 parts of xylooligosaccharide.

In still another embodiment of the present invention, the composite prebiotic comprises 40-200 parts of inulin, 10-140 parts of galacto-oligosaccharide, 1-80 parts of xylitol, and 0.03-5 parts by weight. Yeast β-glucan and 0.1-30 parts of oligomannose.

In still another embodiment of the present invention, the composite prebiotic comprises 70-150 parts of inulin, 20-100 parts of oligogalactose, 1-50 parts of xylitol, 0.05-3 parts by weight. Yeast β-glucan and 0.5-15 parts of oligomannose.

In still another embodiment of the present invention, the composite prebiotic comprises 75 parts of inulin, 23 parts of galactooligosaccharide, 2 parts of xylitol, 0.1 part of yeast β-glucan and 0.8 parts by weight. Composition of oligomannose.

In still another embodiment of the present invention, the composite prebiotic comprises 75 parts of inulin, 23 parts of galacto-oligosaccharide, 2 parts of xylitol, 0.1 part of yeast β-glucan and 8 parts by weight. Composition of xylooligosaccharides.

Another aspect of the invention provides the use of the above-described composite prebiotics for regulating intestinal function in a human.

Another aspect of the present invention provides the above-mentioned composite prebiotics for preparing foods and/or health care products and/or medicines for reducing intestinal gas production and/or increasing intestinal Lactobacillus bacteria and/or increasing the number of Bifidobacterium bacteria in the intestinal tract. Use in.

In a specific embodiment of the present invention, the above composite prebiotic is used for preparing a food, a health care product or a medicine for reducing intestinal gas production, improving intestinal Lactobacillus bacteria, and increasing the number of Bifidobacterium bacteria in the intestinal tract.

Another aspect of the invention provides the use of a carbohydrate comprising inulin, galactooligosaccharide, xylitol, oligomannose and yeast beta-glucan for regulating intestinal function in a human.

Another aspect of the present invention provides a carbohydrate containing inulin, galactooligosaccharide, xylitol, oligomannose, and yeast β-glucan for reducing intestinal gas production and/or reducing intestinal production of short-chain fatty acids. And/or use in the treatment of Lactobacillus bacteria in the gut and/or in foods and/or health supplements and/or pharmaceuticals for increasing the number of Bifidobacterium bacteria in the gut.

Another aspect of the present invention provides a composite prebiotic comprising inulin, galactooligosaccharide, xylitol, oligomannose and yeast β-glucan in the preparation of a reduced intestinal gas production, an increase in intestinal Lactobacillus bacteria and Use in the food and/or health care products and/or pharmaceuticals of the number of Bifidobacterium bacteria in the gut.

Another aspect of the present invention provides a method of reducing intestinal gas production and/or increasing intestinal Lactobacillus bacteria and/or increasing the number of Bifidobacterium bacteria in the intestinal tract, comprising using or comprising a prebiotic comprising the above-described compound prebiotics Food or health supplement.

In a specific embodiment of the invention, the intestinal gas production is caused by inulin.

The invention selects several natural prebiotics for combination, and plays a synergistic effect, and adds ingredients capable of enhancing intestinal immunity, thereby improving intestinal health in all aspects. The compound prebiotics are mainly composed of natural ingredients, and the taste is to maintain the original original flavor, which is convenient for consumers to mix and match according to their preferences. It has been verified by in vitro fermentation experiments that the composite prebiotics combine inulin, galacto-galactose, xylitol, oligomannose and yeast β-glucan to improve the inulin and try to improve the inulin. Exhaust, flatulence, etc. do not respond.

DRAWINGS

1 is a graph showing the results of gas production experiments of all volunteers at 24 hours according to an embodiment of the present invention, wherein Y is a youth group: 20-40 years old; O is an elderly group: 40-60 years old.

2 is a graph showing the results of gas production experiments of the youth group (left panel) and the elderly group (right panel) at 24 hours provided in the examples of the present invention.

3 is a diagram showing the results of detecting thin layer chromatography of all volunteers for 24 h and 48 h according to an embodiment of the present invention, wherein Y is a youth group: 20-40 years old; O is an elderly group: 40-60 years old.

4 is a diagram showing the results of thin layer chromatography detection of the detection youth group 24h (left image) and 48h (right panel) provided in the embodiment of the present invention.

FIG. 5 is a diagram showing the results of thin layer chromatography detection of the aged group 24h (left image) and 48h (right panel) provided in the embodiment of the present invention.

Figure 6 is a graph showing the results of detecting total short-chain fatty acids of all volunteers for 24h and 48h provided in the examples of the present invention, wherein Y is a youth group: 20-40 years old; O is an elderly group: 40-60 years old.

Fig. 7 is a graph showing the results of detecting total short-chain fatty acids in a youth group for 24 hours according to an embodiment of the present invention.

Figure 8 is a graph showing the results of detection of total short-chain fatty acids in the young group for 48 hours, which is provided in the examples of the present invention.

Fig. 9 is a graph showing the results of detecting total short-chain fatty acids in the aged group for 24 hours, which is provided in the examples of the present invention.

Fig. 10 is a graph showing the results of detecting total short-chain fatty acids in the aged group for 48 hours, which is provided in the examples of the present invention.

Fig. 11 is a graph showing the results of analysis of the composition of the flora of the youth group at 48 hours according to the embodiment of the present invention.

Fig. 12 is a graph showing the results of analysis of the composition of the flora in the aged group at 48 hours according to the embodiment of the present invention.

Figure 13 is a graph showing the results of cluster analysis of the genus Bacterial genus of the youth group provided in the examples of the present invention.

Figure 14 is a graph showing the results of cluster analysis of bacterial genus in the elderly group provided in the examples of the present invention.

FIG. 15 is a diagram showing the results of the youth group LefSe analysis provided in the embodiment of the present invention.

Figure 16 is a graph showing the results of analysis of the elderly group LefSe provided in the embodiment of the present invention.

Figure 17 is a graph showing the results of analysis of Lactobacillus bacteria contents of all volunteers provided in the examples of the present invention, wherein Y is a youth group: 20-40 years old; O is an elderly group: 40-60 years old.

Fig. 18 is a graph showing the results of analysis of the contents of Lactobacillus bacteria in the youth group provided in the examples of the present invention.

Fig. 19 is a graph showing the results of analysis of the contents of Lactobacillus bacteria in the elderly group provided in the examples of the present invention.

20 is a graph showing the results of analysis of Bifidobacterium bacteria content of all volunteers provided in the examples of the present invention, wherein Y is a youth group: 20-40 years old; O is an elderly group: 40-60 years old.

Figure 21 is a graph showing the results of analysis of the content of Bifidobacterium bacteria in the youth group provided in the examples of the present invention.

Fig. 22 is a graph showing the results of analyzing the content of Bifidobacterium bacteria in the elderly group provided in the examples of the present invention.

Detailed ways

The technical solutions in the embodiments of the present invention are clearly and completely described below. It is obvious that the described embodiments are only a part of the embodiments of the present invention, and not all of the embodiments. All other embodiments obtained by those skilled in the art based on the embodiments of the present invention without creative efforts are within the scope of the present invention.

The experimental methods used in the following examples are conventional methods unless otherwise specified.

The materials, reagents and the like used in the following examples are commercially available unless otherwise specified.

The invention is described in detail below with reference to the specific embodiments, which are intended to be understood

Example 1 composite prebiotics

The composite prebiotics in this embodiment include inulin, galactooligosaccharide, xylitol and yeast β-glucan, and the inulin is 40-200 parts by weight; the galacto-oligosaccharide is 10-140 parts; Xylitol is 1-80 parts; yeast β-glucan is 0.03-5 parts. Preferably, the inulin is 50-160 parts by weight; the oligogalactose is 20-100 parts; the xylitol is 1-50 parts; and the yeast β-glucan is 0.05-3 parts. More preferably, the inulin is 70-100 parts by weight; the oligogalactose is 20-70 parts; the xylitol is 1-20 parts; the yeast β-glucan is 0.05-1 part. The specific content is shown in Table 1 below.

Table 1 Example 1 content of each component

Instance	Inulin	Oligogalactose	Xylitol	Yeast beta-glucan
1-A	40	30	1	0.03
1-B	85	20	13	0.5
1-C	100	60	5	0.2
1-D	50	10	3	0.1
1-E	160	70	80	1
1-F	120	140	20	5
1-G	200	100	50	3
1-H	54	39	7	0.7

Example 2 composite prebiotics

The composite prebiotics in this embodiment include inulin, galactooligosaccharide, xylitol, yeast β-glucan and xylooligosaccharide, and the inulin is 40-200 parts by weight; galactooligosaccharide It is 10-140 parts; xylitol is 1-80 parts; yeast β-glucan is 0.03-5 parts; xylooligosaccharide is 5-60 parts. Preferably, the inulin is 50-160 parts by weight; the oligogalactose is 20-100 parts; the xylitol is 1-50 parts; the yeast β-glucan is 0.05-3 parts; the oligomeric wood The sugar is 7-30 parts. More preferably, the inulin is 70-100 parts by weight; the oligogalactose is 20-70 parts; the xylitol is 1-20 parts; the yeast β-glucan is 0.05-1 part; Xylose is 7-20 parts. The specific content is shown in Table 2 below.

Table 2 Example 2 content of each component

Instance	Inulin	Oligogalactose	Xylitol	Yeast beta-glucan	Xylooligosaccharide
2-A	40	26	1	0.03	7
2-B	85	20	13	0.5	5
2-C	100	56	5	0.2	15
2-D	50	10	3	0.1	5
2-E	160	50	80	1	20
2-F	120	83	20	5	60
2-G	200	72	50	3	30
2-H	54	30	7	0.7	10

Example 3 composite prebiotics

The composite prebiotics in this embodiment include inulin, galactooligosaccharide, xylitol, yeast β-glucan and oligomannose, and the inulin is 40-200 parts by weight; galactooligosaccharide It is 10-140 parts; xylitol is 1-80 parts; yeast β-glucan is 0.03-5 parts; and oligomannose is 0.1-30 parts. Preferably, the inulin is 50-160 parts by weight; the oligogalactose is 20-100 parts; the xylitol is 1-50 parts; the yeast β-glucan is 0.05-3 parts; the oligomeric nectar The sugar is 0.2-20 parts. More preferably, the inulin is 70-100 parts by weight; the oligogalactose is 20-70 parts; the xylitol is 1-20 parts; the yeast β-glucan is 0.05-1 part; The mannose is 0.5-10 parts. The specific content is shown in Table 3 below.

Table 3 The content of each component in Example 3

Instance	Inulin	Oligogalactose	Xylitol	Yeast beta-glucan	Oligomannose
3-A	40	26	1	0.03	0.1
3-B	85	20	13	0.5	0.2
3-C	100	56	5	0.2	0.5
3-D	50	10	3	0.1	5
3-E	160	50	80	1	10
3-F	120	83	20	5	20
3-G	200	72	50	3	30
3-H	75	twenty three	2	0.1	0.8

Example 4 Effect of various compound prebiotics on human intestinal function

The composite prebiotics in Example 1, Example 2 and Example 3 were used as samples to examine their effects on intestinal function in humans. Separate inulin was used as 4, and starch was used as a control.

YCFA medium of different sugar sources was prepared by using Example 1, Example 2, Example 3, inulin 4 alone and control starch as carbon sources in the medium, respectively. Randomly selected 15 volunteers from the healthy youth group (20-40 years old) and the elderly group (40-60 years old) who had no disease in the intestine and had no antibiotics in the past three months. The average fecal suspension of each volunteer was averaged. Divided into five parts and inoculated into five kinds of YCFA medium and cultured at a constant temperature. Air pressure and thin layer chromatography were detected 24 hours after in vitro vial fermentation, and thin layer chromatography and gas chromatography were performed after 48 hours. After 48 hours, the DNA in the fermentation broth was extracted for microbial diversity analysis. The specific method is as follows:

First, the preparation of the medium

1. Formulation of YCFA medium

Tryptone 10g/L, yeast extract 2.5g/L, L-cysteine 1g/L, heme 2mlg/L, NaCl 0.9g/L, CaCl ₂ ·6H ₂ O 0.09g/L, KH ₂ PO ₄ 0.45 g / L, K ₂ HPO ₄ 0.45 g / L, MgSO ₄ · 7H ₂ O 0.09 g / L, vitamin I ₂₀₀ ug / L, resazurin (1 mg / ml) 1 ml / L, sugar 8 g / L.

2. Preparation of five mediums

The five media are:

The composite prebiotics in the above Examples 1-3 were separately added to YCFA medium as a test medium. For example, the 1-H complex prebiotic in Example 1 was added to YCFA medium to form 1-H medium, referred to as 1-H, and so on. The starch was added to the YCFA as the negative control medium, abbreviated as STA; the inulin was added to the YCFA as the positive control medium, referred to as 4 .

Each medium was prepared in 200 ml, and then dispensed into vials, each of which was 5 ml, packed and sealed, then sterilized by autoclaving at 121 ° C for 30 min, and then stored at room temperature for use.

Second, the volunteer's stool sample collection and inoculation

A total of 30 healthy volunteers who had no disease in the intestine and who did not take antibiotics in the past three months were selected. According to the youth group (20-40 years old) and the elderly group (40-60 years old), the number of men and women in each group is similar.

The basic information of volunteers is as follows:

Inoculation method: (1) Each volunteer was given a sterile tool for collecting feces, and after collecting the original fresh feces, a 10% suspension was prepared with PBS buffer. The fecal suspension was inoculated into five mediums with a sterile syringe, the pressure in the vial was recorded with a barometer, and the inoculation time was recorded, and then placed in a 37 ° C incubator. (2) After 24 hours of inoculation, the pressure in the vial was measured with a barometer, and two tubes of fermentation broth were stored frozen (1 ml each). (3) The remaining fermentation broth was taken for cryopreservation (1.5 ml each) after 48 h of inoculation.

The gas pressure values in the 0h and 24h vials were measured as shown in Table 4 below.

Table 4 Pressure values in 0h and 24h vials

The results of the gas production test for all volunteers are shown in Figures 1 and 2.

From Figures 1 and 2, it is concluded that: (1) the gas production of the youth group is significantly lower than that of the elderly group. (2) Example 2 and Example 3 The gas production amount was lower than that of Example 1 and the individual inulin 4.

Third, the treatment of fermentation broth

The fermentation broths of 24h and 48h were separately centrifuged, 50ul supernatant was dispensed for TLC detection, 500ul+100ul crotonic acid was mixed, frozen for 24h for SCFA detection, and the precipitate was collected for DNA detection. Diversity.

1.TLC detection

In order to detect the glycogen decomposition in the sample, thin layer chromatography analysis was carried out with 24h and 48h fermentation broth, and the decomposition of sugar was scored according to the results of thin layer chromatography. The higher the score, the more complete the degradation. The scoring results and TLC test results are shown in Figures 3 and 5. Figure 3 shows the TLC results of the young and old groups at 24h and 48h respectively. Figure 4 shows the TLC results of the young group at 24h and 48h respectively. Figure 5 shows the TLC results of the old group at 24h and 48h respectively. Figure.

As can be seen from Figures 3 to 5, (1) Example 1 is easily degraded naturally at room temperature; (2) Examples 1-3 and Inulin 4 alone are more fully degraded over time, but There was no significant difference in the degree of degradation between the four groups of samples in the same age group; (3) The young group had better degradation ability to Examples 1-3 and Inulin 4 alone than the old group.

2. Analysis of detection results of short-chain fatty acids (SCFA)

The concentrations of acetic acid, propionic acid, butyric acid, isobutyric acid, valeric acid, and isovaleric acid in the fermentation broth of each of the samples of 24 h and 48 h were measured by gas chromatography. The sum of the above six acids is the concentration of total short-chain fatty acids. The experimental results are shown in Figures 6-10.

As can be seen from Fig. 6-10, (1) Regardless of the single fatty acid or the total short-chain fatty acid, Examples 1-3 and Inulin 4 alone showed no significant difference in acid production between the young group and the elderly group; (2) The acid production in the young group was slightly higher than that in the elderly group. (3) Most of the acid was not significantly different between the youth group and the elderly group regardless of the group or group.

3. Analysis of specific bacterial composition

After 48 hours of fermentation, the bacterial pellet was centrifuged for DNA extraction, and then sent to the sequencing company for detection. The experimental results and analysis are shown in Figures 11-16.

As can be seen from Figures 11-16, for the youth or elderly groups, Examples 1-3 and Inulin 4 alone had no significant effect on the overall flora.

4. Analysis of the content of bacteria in Lactobacillus

The effect of each sample on the bacterial content of Lactobacillus in volunteers was determined as shown in Figures 17-19. As can be seen from Fig. 17-19, Example 3 and the inulin 4 alone have better ability to promote lactic acid bacteria, and the difference between Example 1 and Example 2, Example 3 and Separate Inulin 4 is not significant; The group, Example 3, and inulin 4 alone were significantly different from the control group, but the difference between the groups was not significant.

5. Analysis of bacterial content of Bifidobacterium

The effect of each sample on the bacterial content of the intestinal Bifidobacterium in the volunteers was determined as shown in Figs. 20 to 22 . As can be seen from Fig. 20 to Fig. 22, Example 3 and the inulin 4 alone have a better ability to promote the growth of bifidobacteria, but the difference between the groups is not significant; for the elderly group, Example 3, inulin alone 4 There were significant differences between the two groups, but the differences between the groups were not significant.

According to the above experimental analysis, Examples 1-3 and Inulin 4 alone did not significantly differ in the production of short-chain fatty acids and regulation of the overall intestinal flora, wherein Example 3, individual inulin 4 had a greater than Example 1 and Example 2 The ability to better promote the growth of Lactobacillus and Bifidobacterium was slightly higher for the promotion of Bifidobacterium ability Example 3, while the gas production of Example 3 in the youth group was lower than that of Inulin alone 4.

It can be seen that when the components capable of functioning as a prebiotic are mixed, some of them can enhance the action of the respective components, so that the effect of the composite prebiotic formed after the mixing is better (for example, the prebiotic formula in the third embodiment). However, when some ingredients are added, not only can not enhance the beneficial effects of other prebiotic ingredients, but the effect of the composite prebiotics after mixing can be significantly reduced (for example, the prebiotic formulas provided in Examples 1 and 2).

In summary, the products of Examples 1-3 provided by the present invention are all capable of functioning as prebiotics, but Example 3 has the best effect. For both youth and old age, Example 3 can regulate the intestinal flora and regulate the intestinal function of the human body.

The invention adopts an in vitro fermentation experiment, and examines the gas production, acid production, and microbial diversity of the sample, and selects a health product which can really improve the intestinal tract which is helpful to the human body, and can truly be used for the human intestinal flora. The structure plays a regulatory role in the prebiotic formula.

The above is only the preferred embodiment of the present invention, and is not intended to limit the present invention. Any modifications, equivalent substitutions, etc., which are within the spirit and principles of the present invention, should be included in the scope of the present invention. within.

Claims (10)

1. A composite prebiotic comprising inulin, galactooligosaccharide, xylitol and yeast beta-glucan.
2. The composite prebiotic of claim 1 further comprising xylooligosaccharide and/or oligomannose.
3. The composite prebiotic according to claim 1 or 2, which is composed of inulin, galactooligosaccharide, xylitol, xylooligosaccharide and yeast β-glucan, or inulin, galacto-oligosaccharide, wood It consists of sugar alcohol, oligomannose and yeast β-glucan.
4. The composite prebiotic according to any one of claims 1 to 3, wherein the inulin is 40-200 parts by weight; the galacto-oligosaccharide is 10-140 parts; and the xylitol is 1-80 parts; the yeast β-glucan is 0.03-5 parts, and optionally, further includes 5-60 parts of xylooligosaccharide and/or 0.1-30 parts of oligomannose.
5. The composite prebiotic according to claim 4, wherein the inulin is 70-100 parts by weight; the oligogalactose is 20-70 parts; and the xylitol is 1-20 parts; The yeast β-glucan is 0.05-1 parts, and optionally, 7-20 parts of xylooligosaccharide and/or 0.5-10 parts of oligomannose.
6. The composite prebiotic according to claim 5, which comprises 75 parts of inulin, 23 parts of galacto-oligosaccharide, 2 parts of xylitol, 0.1 part of yeast β-glucan and 0.8 part of oligomannan in terms of parts by weight. The sugar composition, or it consists of 75 parts of inulin, 23 parts of galactooligosaccharide, 2 parts of xylitol, 0.1 part of yeast β-glucan and 8 parts of xylooligosaccharide.
7. Use of the composite prebiotic according to any one of claims 1 to 6 for regulating intestinal function in a human.
8. The composite prebiotic according to any one of claims 1 to 6 for the preparation of foods and/or health care for reducing intestinal gas production and/or increasing intestinal Lactobacillus bacteria and/or increasing the number of Bifidobacterium bacteria in the intestinal tract Use in products and / or medicines.
9. The use according to claim 8, wherein the composite prebiotic is used for the preparation of a food, a health supplement or a medicine for reducing intestinal gas production, increasing the number of bacteria of the genus Bifidobacterium in the intestinal tract and bacteria in the intestinal tract.
10. Lowering intestinal gas production (preferably, the gas production is caused by inulin) and/or improving the number of Lactobacillus bacteria in the gut and/or increasing the number of Bifidobacterium bacteria in the gut, including the use of rights A compound prebiotic according to any one of claims 1 to 6 or a food or health supplement comprising the prebiotic.

Images